2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Bi De Pharmaceutical (688073.SH) released its half-year performance with a net income of 51.8391 million yuan, a year-on-year decrease of 38.15%.
BiDe Pharmaceutical (688073.SH) released its 2024 interim report, with a revenue of 0.532 billion yuan...
BiDe Pharmaceutical (688073.SH): The net income in the first half of the year was 51.8391 million yuan, a year-on-year decrease of 38.15%.
On August 28, Bairui Pharmacy (688073.SH) announced its semi-annual report. The company achieved a revenue of 532.2073 million yuan during the reporting period, a year-on-year growth of 1.83%. The net income attributable to the parent company was 51.8391 million yuan, a year-on-year decrease of 38.15%. Overseas income continued to grow rapidly, and the proportion of overseas income continued to increase. In terms of revenue during the reporting period, overseas income amounted to 299.3019 million yuan, accounting for 56.24%, compared to 265.6107 million yuan, accounting for 50.83% in the same period last year. The overseas income in the first half of 2024 increased year-on-year.
Bide Pharmaceutical (688073.SH) has repurchased 2.81% of its shares for a total cost of 99.99 million yuan.
On July 8th, Gelunhui reported that as of July 5, 2024, Bi De Pharmaceutics (688073.SH) used centralized bidding trading to repurchase a total of 2,554,024 shares of the company's stock, accounting for 2.8102% of the total share capital. The highest repurchase price was 52.99 yuan/share, the lowest price was 28.63 yuan/share, the average repurchase price was 39.15 yuan/share, and the total amount of funds paid was RMB 99,991,734.50 (excluding transaction fees). The company's repurchase amount has reached the lower limit of the repurchase funds in the repurchase program and has not exceeded the total repurchase funds.
Bide Pharmaceutical (688073.SH): Dai Lan accumulatively increased the shareholding of the company by 2.5572 million yuan.
On June 28, Gelunhui announced that Ms. Dai Lan has accumulated 70,090 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding from January 24, 2024 to June 27, 2024. The shareholding accounts for 0.0771% of the total share capital of the company, and the total shareholding amount is RMB 2.5572 million (excluding transaction costs). It has exceeded the lower limit amount of RMB 2.5 million for this shareholding plan, and this shareholding plan has been fully implemented.
Bi De Pharmaceutical (688073.SH): Dinghua Yongchuang partners meeting reviewed and approved the resolution to dissolve and liquidate the partnership enterprise.
On June 18th, Gelunhui reported that Bidet Pharmaceuticals (688073.SH) recently received a notice from shareholder Dinghua Yongchuang to dissolve and liquidate the partnership enterprises at the Dinghua Yongchuang partner meetings. Dinghua Yongchuang will apply to the Shanghai branch of China Securities Depository and Clearing Corporation Limited for non-transaction equity transfer matters of its holding company's shares. After this change in equity, the number of shares held by relevant shareholders and concerted actors is 10,110,685 shares, and the proportion of the company's total share capital held decreased from 12.76% to 11.12%.
BeiDe Pharmaceutical (688073.SH) will distribute cash dividends for the year 2023 on June 26, with a dividend of 0.9 yuan per share.
BiDe Pharmaceutical (688073.SH) announced that it will issue the 2023 annual report on June 26, 2024...
Bide Pharmaceutical (688073.SH): Has repurchased 2.3426% of the company's shares.
On June 4th, Gelonhui reported that Bi De Pharmaceutical (688073.SH) has announced that as of May 31, 2024, the company has cumulatively repurchased 2,129,043 shares of the company through the Shanghai Stock Exchange trading system by means of centralized competitive bidding, accounting for 2.3426% of the total share capital of 90,882,948 shares. The highest repurchase price was 52.99 yuan/share and the lowest price was 31.01 yuan/share. The total amount of the transaction was 87,420,246.76 yuan (excluding transaction fees).
Bide Pharmaceutical (688073.SH): It sells such paraphthalic anhydride products
Gelonghui, May 9 | Bide Pharmaceutical (688073.SH) said on the investor interactive platform that the company sells such paraphthalic anhydride products.
Bide Pharmaceutical (688073.SH): 2.3426% of shares have been repurchased in total
Gelonghui, May 6, 丨 Bide Pharmaceutical (688073.SH) announced that as of April 30, 2024, the company had repurchased 2,129,043 shares of the company's shares through centralized bidding transactions, accounting for 2.3426% of the company's total share capital of 90,882,948 shares, an increase of 0.2751% compared with the disclosure of the previous repurchase progress. The highest price of the repurchase transaction was 52.99 yuan/share. The lowest price was 31.01 yuan/share, and the total transaction amount was 87,420,246.76 yuan (not included) transaction fees).
Bide Pharmaceutical (688073.SH) announced its 2023 annual results, net profit of 110 million yuan decreased by 24.94% year-on-year
Bide Pharmaceutical (688073.SH) released its 2023 annual performance report. The company achieved operating income of 1 during the reporting period...
Bide Pharmaceutical (688073.SH): Currently, the cooperation with Huawei is still small
On April 17, Ge Longhui Pharmaceutical (688073.SH) said on the investor interactive platform that Bide Pharmaceutical's main business is to provide customers with products or services related to “molecular blocks and scientific research reagents”. Currently, the company's cooperation with Huawei is still small. If the amount of subsequent orders meet the disclosure standards, it will fulfill its obligation to disclose information. The field of new materials has very good potential for development, and the company has always kept a close eye on it.
Bide Pharmaceutical (688073.SH): A total of 2.0675% of the company's shares have been repurchased
Gelonghui, April 10 | Bide Pharmaceutical (688073.SH) announced that as of April 9, 2024, the company had repurchased a total of 1.889,000 shares of the company's shares through the Shanghai Stock Exchange trading system, accounting for 2.0675% of the company's total share capital of 90,882,948 shares, an increase of 0.2893% compared with the previous disclosure. The highest price of the repurchase transaction was 52.99 yuan/share. The lowest price was 32.36 yuan/share, and the total transaction amount was 794.819 million yuan (excluding transaction fees).
Bide Pharmaceutical (688073.SH): Did not buy back the company's shares in March
Gelonghui, April 1 | Bide Pharmaceutical (688073.SH) announced that in March 2024, the company did not buy back the company's shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. As of March 31, 2024, the company has repurchased a total of 1,616,155 shares through the Shanghai Stock Exchange trading system, accounting for 1.7783% of the company's total share capital of 90,882,948 shares. The highest price of the repurchase transaction was 52.99 yuan/share, the lowest price was 32.36 yuan/share, and the total transaction amount was 70,431,395
Are Bide Pharmatech Co., Ltd.'s (SHSE:688073) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Bide Pharmaceutical (688073.SH): Dai Lan increased its holdings by 35,000 shares
Gelonghui, March 20, 丨 Bide Pharmaceutical (688073.SH) announced that from January 24, 2024 to March 19, 2024, Ms. Dai Lan has accumulated 35,000 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.0385% of the company's total share capital. The total increase amount is RMB 1.407 million (excluding transaction fees), which has exceeded 50% of the minimum amount of RMB 2.5 million of the current increase plan. Entities that increase their holdings will continue to increase their public holdings during the implementation period of the plans to increase their holdings in accordance with the relevant plans to increase their holdings
Bide Pharmaceutical (688073.SH): The company has not used AI technology
Gelonghui, March 20 | Bide Pharmaceutical (688073.SH) said on the investor interactive platform that at present, the company has not used AI technology. At the same time, the company has been keeping an eye on the progress of AI technology in the field of new drug development.
5.162,200 restricted shares of Bide Pharmaceutical (688073.SH) will be listed and circulated on March 25
Bide Pharmaceutical (688073.SH) announced that the restricted shares currently in circulation are part of the company's initial public offering...
Bide Pharmaceutical (688073.SH): It has spent 704.314 million yuan to buy back a total of 1.7783% of the company's shares
Gelonghui, March 4, 丨 Bide Pharmaceutical (688073.SH) announced that as of February 29, 2024, the company had repurchased a total of 1.616,200 shares of the company's shares through the Shanghai Stock Exchange trading system, accounting for 1.7783% of the company's total share capital of 90,882,948 shares. The highest price of the repurchase transaction was 52.99 yuan/share, the lowest price was 32.36 yuan/share, and the total transaction amount was 704.314 million yuan (excluding transaction fees).
No Data
No Data